{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T12:56:54Z","timestamp":1773925014530,"version":"3.50.1"},"reference-count":30,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2016,3,1]],"date-time":"2016-03-01T00:00:00Z","timestamp":1456790400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","gynecologiconcology-online.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2016,3]]},"DOI":"10.1016\/j.ygyno.2015.12.029","type":"journal-article","created":{"date-parts":[[2015,12,31]],"date-time":"2015-12-31T02:51:03Z","timestamp":1451530263000},"page":"559-564","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"title":["A prospective observational study on chemotherapy-induced nausea and vomiting (CINV) in patients with gynecologic cancer by the CINV Study Group of Japan"],"prefix":"10.1016","volume":"140","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3151-8315","authenticated-orcid":false,"given":"Mika","family":"Mizuno","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masamichi","family":"Hiura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fumitaka","family":"Kikkawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fumitaka","family":"Numa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nobuo","family":"Yaegashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hisashi","family":"Narahara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daisuke","family":"Aoki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eizo","family":"Kimura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hisamori","family":"Kato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mototsugu","family":"Shimokawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toru","family":"Sugiyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshiharu","family":"Kamura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ygyno.2015.12.029_bb0005","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1007\/s00520-001-0339-7","article-title":"Nausea and emesis: still an unsolved problem in cancer patients?","volume":"10","author":"Herrstedt","year":"2002","journal-title":"Support. Care Cancer"},{"key":"10.1016\/j.ygyno.2015.12.029_bb0010","doi-asserted-by":"crossref","first-page":"3090","DOI":"10.1002\/cncr.11433","article-title":"Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting. Results from a randomized, double-blind, placebo-controlled trial in Latin America","volume":"97","author":"Poli-Bigelli","year":"2003","journal-title":"Cancer"},{"key":"10.1016\/j.ygyno.2015.12.029_bb0015","doi-asserted-by":"crossref","first-page":"4112","DOI":"10.1200\/JCO.2003.01.095","volume":"21","author":"Hesketh","year":"2003","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2015.12.029_bb0020","doi-asserted-by":"crossref","unstructured":"Prevention of chemotherapy- and radiotherapy-induced emesis: results of Perugia Consensus Conference. Antiemetic Subcommittee of the Multinational Association of Supportive Care in Cancer (MASCC). Ann Oncol. 1998;9:811\u20139.","DOI":"10.1023\/A:1008471812316"},{"issue":"Suppl. 5","key":"10.1016\/j.ygyno.2015.12.029_bb0025","doi-asserted-by":"crossref","first-page":"v232","DOI":"10.1093\/annonc\/mdq194","article-title":"Guideline update for MASCC and ESMO in the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting: results of the Perugia consensus conference","volume":"21","author":"Roila","year":"2010","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ygyno.2015.12.029_bb0030","doi-asserted-by":"crossref","first-page":"4189","DOI":"10.1200\/JCO.2010.34.4614","article-title":"Antiemetics: American Society of Clinical Oncology clinical practice guideline update","volume":"29","author":"Basch","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2015.12.029_bb0035","unstructured":"Oncology Ncpgi. Antiemetics. 2014;Version 2."},{"key":"10.1016\/j.ygyno.2015.12.029_bb0040","unstructured":"Oncology JSoC. Guidelines for appropriate use of antiemetic drugs. Kanehara, Tokyo. 2010;version 1."},{"key":"10.1016\/j.ygyno.2015.12.029_bb0045","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1002\/1097-0142(19890901)64:5<1117::AID-CNCR2820640525>3.0.CO;2-R","article-title":"Prognostic factors influencing cisplatin-induced emesis. Definition and validation of a predictive logistic model","volume":"64","author":"Pollera","year":"1989","journal-title":"Cancer"},{"key":"10.1016\/j.ygyno.2015.12.029_bb0050","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1093\/oxfordjournals.annonc.a057871","article-title":"Methodology of antiemetic trials: a review","volume":"2","author":"Tonato","year":"1991","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ygyno.2015.12.029_bb0055","first-page":"374","article-title":"Chemotherapy-induced nausea and vomiting in breast cancer patients: a prospective observational study","volume":"5","author":"Booth","year":"2007","journal-title":"J Support Oncol."},{"key":"10.1016\/j.ygyno.2015.12.029_bb0060","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1007\/s00520-009-0737-9","article-title":"Evaluation of risk factors predictive of nausea and vomiting with current standard-of-care antiemetic treatment: analysis of two phase III trials of aprepitant in patients receiving cisplatin-based chemotherapy","volume":"18","author":"Hesketh","year":"2010","journal-title":"Support. Care Cancer"},{"key":"10.1016\/j.ygyno.2015.12.029_bb0065","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1200\/JCO.1987.5.1.141","article-title":"Antiemetic activity of high doses of metoclopramide combined with methylprednisolone versus metoclopramide alone in cisplatin-treated cancer patients: a randomized double-blind trial of the Italian Oncology Group for Clinical Research","volume":"5","author":"Roila","year":"1987","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2015.12.029_bb0070","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1200\/JCO.1997.15.1.116","article-title":"Determinants of postchemotherapy nausea and vomiting in patients with cancer. Quality of Life and Symptom Control Committees of the National Cancer Institute of Canada Clinical Trials Group","volume":"15","author":"Osoba","year":"1997","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2015.12.029_bb0075","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1007\/s00520-010-0899-5","article-title":"Evaluation of risk factors predictive of nausea and vomiting with current standard-of-care antiemetic treatment: analysis of phase 3 trial of aprepitant in patients receiving adriamycin-cyclophosphamide-based chemotherapy","volume":"19","author":"Warr","year":"2011","journal-title":"Support. Care Cancer"},{"key":"10.1016\/j.ygyno.2015.12.029_bb0080","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1007\/s00404-013-3058-7","article-title":"Evaluation of the relation between patient characteristics and the state of chemotherapy-induced nausea and vomiting in patients with gynecologic cancer receiving paclitaxel and carboplatin","volume":"289","author":"Furukawa","year":"2014","journal-title":"Arch. Gynecol. Obstet."},{"key":"10.1016\/j.ygyno.2015.12.029_bb0085","unstructured":"Center NC. Center for Cancer Control and Information Services. Web site http:\/\/ganjohojp\/Japan."},{"key":"10.1016\/j.ygyno.2015.12.029_bb0090","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1093\/jnci\/djg036","article-title":"A randomized clinical trial of cisplatin\/paclitaxel versus carboplatin\/paclitaxel as first-line treatment of ovarian cancer","volume":"95","author":"du Bois","year":"2003","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.ygyno.2015.12.029_bb0095","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1200\/JCO.2004.00.7617","article-title":"Randomized phase III trial of whole-abdominal irradiation versus doxorubicin and cisplatin chemotherapy in advanced endometrial carcinoma: a Gynecologic Oncology Group Study","volume":"24","author":"Randall","year":"2006","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2015.12.029_bb0100","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1093\/annonc\/mdq401","article-title":"Randomized phase II study comparing docetaxel plus cisplatin, docetaxel plus carboplatin, and paclitaxel plus carboplatin in patients with advanced or recurrent endometrial carcinoma: a Japanese Gynecologic Oncology Group study (JGOG2041)","volume":"22","author":"Nomura","year":"2011","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ygyno.2015.12.029_bb0105","doi-asserted-by":"crossref","DOI":"10.1007\/s10147-015-0786-7","article-title":"Testing the effectiveness of antiemetic guidelines: results of a prospective registry by the CINV Study Group of Japan","author":"Tamura","year":"2015","journal-title":"Int. J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2015.12.029_bb0110","doi-asserted-by":"crossref","first-page":"1986","DOI":"10.1093\/annonc\/mds021","article-title":"The effect of guideline-consistent antiemetic therapy on chemotherapy-induced nausea and vomiting (CINV): the Pan European Emesis Registry (PEER)","volume":"23","author":"Aapro","year":"2012","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ygyno.2015.12.029_bb0115","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.ejphar.2013.09.073","article-title":"International antiemetic guidelines on chemotherapy induced nausea and vomiting (CINV): content and implementation in daily routine practice","volume":"722","author":"Jordan","year":"2014","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.ygyno.2015.12.029_bb0120","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1007\/s00520-007-0343-7","article-title":"A prospective observational study of chemotherapy-related nausea and vomiting in routine practice in a UK cancer centre","volume":"16","author":"Molassiotis","year":"2008","journal-title":"Support. Care Cancer"},{"key":"10.1016\/j.ygyno.2015.12.029_bb0125","doi-asserted-by":"crossref","first-page":"2822","DOI":"10.1200\/JCO.2005.09.050","article-title":"Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer after moderately emetogenic chemotherapy","volume":"23","author":"Warr","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2015.12.029_bb0130","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1038\/bjc.2013.400","article-title":"A randomised, placebo-controlled, double-blind study of aprepitant in nondrinking women younger than 70years receiving moderately emetogenic chemotherapy","volume":"109","author":"Tanioka","year":"2013","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.ygyno.2015.12.029_bb0135","doi-asserted-by":"crossref","first-page":"2701","DOI":"10.1002\/cncr.20718","article-title":"Patient expectation is a strong predictor of severe nausea after chemotherapy: a University of Rochester Community Clinical Oncology Program study of patients with breast carcinoma","volume":"101","author":"Roscoe","year":"2004","journal-title":"Cancer"},{"key":"10.1016\/j.ygyno.2015.12.029_bb0140","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/j.jpainsymman.2013.06.012","article-title":"Evaluation of risk factors predicting chemotherapy-related nausea and vomiting: results from a European Prospective Observational Study","volume":"47","author":"Molassiotis","year":"2014","journal-title":"J. Pain Symptom Manag."},{"key":"10.1016\/j.ygyno.2015.12.029_bb0145","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1007\/s00520-005-0788-5","article-title":"Incidence of chemotherapy-induced nausea and vomiting in Taiwan: physicians' and nurses' estimation vs. patients' reported outcomes","volume":"13","author":"Liau","year":"2005","journal-title":"Support. Care Cancer"},{"key":"10.1016\/j.ygyno.2015.12.029_bb0150","doi-asserted-by":"crossref","first-page":"2261","DOI":"10.1002\/cncr.20230","article-title":"Incidence of chemotherapy-induced nausea and emesis after modern antiemetics","volume":"100","author":"Grunberg","year":"2004","journal-title":"Cancer"}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825815302328?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825815302328?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,16]],"date-time":"2018-09-16T08:28:22Z","timestamp":1537086502000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825815302328"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,3]]},"references-count":30,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2016,3]]}},"alternative-id":["S0090825815302328"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2015.12.029","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2016,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A prospective observational study on chemotherapy-induced nausea and vomiting (CINV) in patients with gynecologic cancer by the CINV Study Group of Japan","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2015.12.029","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}